Tag: 1a/2a

Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer
Health

Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer

DPTX3186, a first-in-class beta-catenin condensate modulator, received Orphan Drug Designation and Fast…

GlobeNews Wire
GlobeNews Wire